Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chiasma, Inc.
Analysts Impressed By Amryt As EB Drug Action Date Approaches
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
Gilead’s Long-Acting HIV Drug Among Latest EU Filings
The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.
Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings
Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.
Amryt Predicts $1bn Revenues After Chiasma Acquisition
The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.
- Drug Delivery
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.